These authors contributed equally to this work.
Simple polyglutamine (polyQ) peptides aggregate in vitro via a nucleated growth pathway directly yielding amyloid-like aggregates. We show here that the 17 amino acid flanking sequence (httNT) N-terminal to the polyQ in the toxic huntingtin exon1 fragment imparts onto this peptide a complex alternative aggregation mechanism. In isolation the httNT peptide is a compact coil that resists aggregation. When polyQ is fused to this sequence, it induces in httNT, in a repeat-length dependent fashion, a more extended conformation that greatly enhances its aggregation into globular oligomers with httNT cores and exposed polyQ. In a second step, a new, amyloid-like aggregate is formed with a core composed of both httNT and polyQ. The results indicate unprecedented complexity in how primary sequence controls aggregation within a substantially disordered peptide, and have implications for the molecular mechanism of Huntington's disease.
There are nine known expanded CAG repeat diseases, in which expansion of a disease protein's polyglutamine (polyQ) sequence beyond a threshold repeat length causes progressive neurodegeneration through a predominantly gain-of-function mechanism
Not all data support this hypothesis, however. In particular, in cell and animal models disease progression is not always correlated with aggregate burden as measured by inclusions revealed by light microscopy
Although the human
Intrigued by these oligoproline effects, we turned our attention to the 17 amino acid sequence at the N-terminus of the huntingtin protein, just upstream from the polyQ segment. In this paper, we describe detailed analysis of the in vitro aggregation mechanism of chemically synthesized peptide models for human huntingtin exon1 that include this 17 amino acid sequence (httNT). We show that addition of httNT to polyQ causes dramatic changes in the aggregation mechanism, intermediates and products. We also show that this behavior is grounded in a kind of reciprocal crosstalk between the polyQ and httNT segments, both of which are intrinsically unfolded protein sequences
To explore possible effects of the htt exon1 N-terminal 17 amino acids on polyQ aggregation, we generated the peptide httNTQ35 (
In spite of the apparent dominant effect by the httNT sequence, the kinetics of a series of httNTQN peptides continues to exhibit a strong polyQ repeat length dependence, as shown previously for both simple polyQ peptides
Previously, we found that early stages of the aggregation of simple polyQ peptides exhibit a modest concentration dependence consistent with a nucleated growth polymerization mechanism and a critical nucleus of one
Previously, we found that when simple polyQ monomers undergo spontaneous aggregation in aqueous solution, the earliest observable aggregates have fibril-associated properties similar to those of the final product
There are a number of possible explanations for the aggregation-enhancing ability of the httNT sequence. (I.) Since addition of lysine residues to a sequence sometimes discourage aggregation
Arguing against this postulated polyQ-induced unfolding mechanism for the httNT effect is the fact that most peptides the size of httNT do not fold into stable, globular structures, but rather are disordered. Interestingly, however, analytical SEC suggests that the httNT sequence is actually relatively compact in solution. A series of simple polyQ peptides yield migration rates in SEC that fit a straight line (
To confirm the compactness of the httNT peptide, we conducted a fluorescence-based resonance energy transfer (FRET) experiment in which we replaced Met1 of httNT with the resonance energy acceptor, nitro-Tyr, and Phe17 with the resonance energy donor Trp
Given this evidence for a collapsed structure in an isolated httNT peptide, we investigated whether it was possible for expanded polyQ sequences to disrupt that collapsed state in peptides dissolved in PBS. We found that for the FRET-exon1 mimic peptide containing a Q20 repeat, the average separation between nitro-Tyr and Trp in the httNT sequence does not significantly change (p > 0.01). However, the corresponding separation for the Q37 repeat peptide expands to 32 ± 1 Å (p < 0.01), a value approaching the 34 Å range obtained both by measurement of httNTQ3 in urea and by calculation based on an assumed statistical coil configuration (
Although several features of the above results are consistent with httNT (in the absence of a connected expanded polyQ) being a compact domain, the short length of httNT makes it unlikely (but not impossible) that it possesses a unique, folded structure. To probe httNT secondary and tertiary structure, we applied two solution methods. The first, CD spectral analysis, proved equivocal. The CD spectrum of httNT at 35 °C (
The CD dichotomy was clarified by high resolution NMR analysis (
Thus, in the absence of an expanded polyQ, httNT adopts a conformation lacking significant secondary and tertiary structural features, while at the same time being in a collapsed state. Results from the sequence analysis algorithm PONDR are consistent with this, predicting (
When the assembly of simple polyQ peptides into amyloid-like aggregates is monitored by multiple analytical techniques, the data from all measures track closely, suggesting the absence of reaction intermediates
Details of the structures of these intermediates are revealed by further analysis of httNTQ30P6 (
Thus, the initial aggregates in this httNT mediated mechanism are non-fibrillar oligomers with their httNT segments composing the core, but their polyQ segments remaining unstructured and available for antibody binding. Subsequently, the polyQ elements also become integrated into the aggregate core structure, which takes on a more fibrillar character both in the polyQ and httNT elements. Growth into larger fibrillar assemblies, as seen in EM, take place at later incubation times. FTIR analysis (
Critically, at a time when the major changes in aggregate structure are occurring, as evidenced by ThT binding, Trp fluorescence shift, FTIR, EM, and polyQ antibody binding, the vast bulk of the exon1 peptide (>80%) does not pellet after centrifugation (
The results presented here are consistent with the model shown in
In many respects, the mechanism shown in
Amino acid sequence has been viewed as playing two major roles in influencing protein aggregation and amyloid formation
Perhaps 25% of the proteome consists of sequences that do not exist as ordered globular or fibrous structures, but rather are intrinsically unfolded
We believe httNT derives its unusual impact on aggregation mechanism and rate due to its resemblance to MoRF sequences
Our results add to a growing literature on interactions between polyQ and its flanking sequences in aggregation reactions. After initial reports on the ability of flanking sequences to modulate aggregation of polyQ disease proteins in cells
Our results put into a molecular biophysics context several recent cell-based studies of the role of the httNT sequence in exon1 aggregation and toxicity. Using models in which exon1 fragments are expressed in mammalian or yeast cells, several groups have shown that the presence or absence of httNT, as well as mutations within or adjacent to httNT, introduce complex alterations in sub-cellular localization, aggregate formation, and/or cytotoxicity or growth retardation
All huntingtin-related peptides, as well the Pro14 and Ala-rich peptide “Bal”
The sedimentation assay
Aliquots of whole aggregation reaction mixture were taken at different time points and visualized by electron microscopy. 3 μl of sample were placed on a freshly glow-discharged carbon-coated grid, adsorbed for 2 minutes, washed with deionized water before staining with 2μl of 1% uranyl acetate and blotting. Grids were imaged on a Tecnai T12 microscope (FEI Co., Hillsboro, Oregon) operating at 120kV and 30,000× magnification, and equipped with an UltraScan 1000 CCD camera (Gatan, Pleasanton, California) with post-column magnification of 1.4×.
CD spectra were collected using a Jasco J-810 spectrapolarimeter with a 1 mm pathlength quartz cuvette. HttNT samples were collected in 20 mM Tris-TFA pH 7.2 at concentrations of 20 − 500 μM. The spectra were collected immediately after thawing (from −80 °C) the disaggregated peptide samples. Scans were made at 20 nm per min with steps of 0.5 nm and an averaging time of 8s. The reported spectra are averages taken over 4 scans.
The httNT sample for NMR experiments contained 40 μM peptide in 20mM sodium phosphate buffer (pH 7.2), 0.02 % sodium azide, 6% 2H2O. NMR experiments were carried out on a Bruker Avance 800 MHz NMR spectrometer, equipped with a 5 mm z-axis gradient cryoprobe. The water solvent peak was suppressed using the WATERGATE W5 pulse sequence
Size exclusion chromatography experiments were conducted with a Superdex peptide HR10/30 (Pharmacia Biotech) column on a Bio-Rad (Biologic Duo flow) chromatograph using 1ml min−1 flow rate and detection at 215 nm at ambient temperature. Peptides were suspended in PBS (polyQ peptides and httNT after disaggregation) at 20−100 μM and 100 μL injected. The
FRET peptides (
Peptide concentrations underpinning the FRET determination were made in two different ways, which gave very similar results. In one method, we used amino acid composition analysis (Keck Biotechnology Center, Yale University) to calibrate a stock solution of the peptide which was then used as an HPLC standard for future determinations
Dot blots were performed as described
Aggregates were isolated at different times as described in General Methods, then resuspended in 300 μL 150 mM NaCl, 10 mM phosphate, pH 7.4 and analyzed on a Perkin Elmer luminescence LS50B spectrometer. The samples were excited at 280 nm and emission was scanned between 290 and 550 nm. The wavelength at the emission intensity maximum was recorded.
Fourier transform infrared spectroscopy of various samples was performed using MB series spectrophotometer with PROTA software (ABB Bomem). Protein aggregates were harvested by centrifugation at 20,817 × g and the pellet was washed 3 times with PBS. Spectra of re-suspended aggregates were recorded at 4 cm−1 resolution (400 scans at room temperature). Spectra were corrected for the residual buffer absorption by subtracting the buffer alone spectrum interactively until a flat baseline was obtained between 1,700−1,800 cm−1. Second-derivative spectra for the Amide I region were calculated from the primary spectrum by using PROTA software.
For the Q15 monomer sample, the peptide was purified by reverse phase HPLC with an aqueous acetonitrile gradient in 5 mM HCl to avoid exposure of the peptide to TFA, which gives a large peak in FTIR. Peak fractions were pooled and lyophilized, and the powder dissolved in 50 μl of 1 mM HCl , then centrifuged 1 hr at 435,680 × g. A 25 μl aliquot was carefully removed and mixed with 25 μL of a 2X PBS buffer, centrifuged for 30 mins at 435,680 × g, and the supernatant subjected to analysis. This material appears to contain about 20% by mass of amyloid-like polyQ aggregates, based on ThT analysis, presumably because of its very high concentration (2.4 mM) and the abbreviated and modified disaggregation protocol necessitated by the demands of the experiment.
For the monomer control, httNT was disaggregated and dissolved in pH 3 TFA in water, then added to a solution of trypsin (SEQUENZ-Trypsin, Worthington Biochemical Corporation) in 100 mM Tris-HCl, pH 7.0 to yield a 1:10 ratio of trypsin to peptide in 50 mM Tris. This solution was incubated at room temperature and monitored by injection of aliquots onto a RP-HPLC-MS system (Agilent 1100), which indicated efficient cleavage after the httNT Lys residues (data not shown). Aggregates were harvested and quantified as described in General Methods, then incubated with trypsin at 1:10 w/w (trypsin: peptide) in 50 mM Tris, pH 7.0 at room temperature. LC-MS of digest centrifugation supernatants yielded no material. All the material was found in pellet fractions and was undigested (data not shown).
The elongation of biotinylated Q29 (B-Q29) on httNTQ20P10 aggregates harvested at different times was done as described
For all reaction profiles, datasets were fit in Sigma Plot to either 3-parameter equations (exponential decay, exponential rise to maximum, or sigmoidal) or linear regression. Reported R2 values and standard deviations (“S.D.”) are from the Sigma Plot fits. Many data sets were obtained in duplicate, and those that were not are representative of multiple experiments. The tight error bars for the HPLC sedimentation assay data obtained in duplicate (
The authors acknowledge Jan Ko and Paul Patterson (California Institute of Technology) for a gift of MW1 antibody, and Tim Fullam (Allegheny College) for providing a set of aggregation kinetics data. We also acknowledge the following funding sources that contributed to the work described here: NIH R01 AG019322 (RW); Huntington's Disease Society of America postdoctoral fellowship (VMC); NSF MCB-0444049 (TPC); Petroleum Research Fund / American Chemical Society 43138-AC4 (TPC).
Aggregation kinetics of huntingtin exon1 mimic peptides exploring a variety of polyQ repeat lengths. (A) Basic httNT effect: HPLC sedimentation assay following aggregation of httNT (5 μM, R2=0.746, S.D.= ± 2.3), httNTQ35 (3 μM, R2=0.986, S.D.= ± 4.6), Q35 (25 μM, R2=0.993, S.D.= ± 3.8; 3 μM, R2=0.688, S.D.= ± 1.8), Q35httNT (3 μM, R2=0.996, S.D.= ± 3.0), httNTQ36P10 (3 μM, R2=0.992, S.D.= ± 4.3), Q35P10 (25 μM, R2=0.973, S.D.= ± 0.8), httNTK2Q36 (3 μM, R2=0.981, S.D.= ± 1.0); (B) Role of polyQ repeat length on 5 μM peptides. HPLC sedimentation assay following aggregation of httNT (R2=0.746, S.D.= ±2.3), httNTQ3 (F17W) (R2=0.966, S.D.= ±2.1), httNTQ15 (F17W) (R2=0.971, S.D.= ± 3.2), httNTQ25 (F17W) (R2=0.992, S.D.= ± 3.3), httNTQ35 (R2=0.993, S.D.= ± 4.3); (C) Role of httNT mutations in a httNTQ20P10 peptides (see
Electron micrographs of various httNT-related aggregates. httNTQ30P6 was incubated in PBS at 37 °C and sampled at 0 hrs (A), 15 mins (B), 2.5 hrs (C, D, E), 5.5 hrs (F, G), 24 hrs (H, I), 48 hrs (J) and 100 hrs (K). httNTQ3 (F17W) was incubated in PBS at 37 °C for 800 hrs (L). All samples were transferred directly from reaction mixture to freshly glow-discharged carbon-coated grids and stained with 1% uranyl acetate. Scale bar = 50 nm.
State of expansion of the httNT peptide in solution. (A) Fractional migration (
Concentration dependent circular dichroism spectra of httNT. (A) httNT in aqueous buffer (see Methods) at 35 °C in concentrations of 3.8 μM (———),7.5 μM (······), and 18.9 μM (------). ContinLL
Proton NMR analysis of httNT. (A) Summary of NOE and secondary 1H chemical shift (Δδ Hα) data observed for httNT at 800 MHz, 5 °C in 10 mM phosphate buffer, pH 7.2. The relative intensities of the inter-proton NOEs dαN(i,i), dαN(i,i+1), dNN(i,i+1), dNN(i,i) and dαN(i,i+2) are depicted by the thickness of the lines. The Hα secondary chemical shift values of httNT (Δδ Hα) were calculated by subtracting random coil values
PONDR analysis of the first 600 amino acids of the human huntingtin sequence. Segments with low PONDR scores are predicted to be stably folded, and high scores (near 1) disordered. Short segments spiking below a PONDR score of 0.5 are predicted to be MoRFs (see text). Calculated using the VX-LT version of PONDR. Access to PONDR® was provided by Molecular Kinetics (6201 La Pas Trail - Ste 160, Indianapolis, IN 46268; 317−280−8737; E-mail:
Time course of aggregation of httNTQ30P6 (F17W) by multiple analyses. (A) Fluorescence emission maximum of Trp residue at position 17 in resuspended aggregates isolated from reaction of httNTQ30P6 (F17W) (■) or httNTQ3 (F17W) (Δ). The emission maximum of monomeric peptide (•) is plotted as being equivalent to that of initial aggregates, since this is the result obtained for the F17W mutant of the shorter, less rapidly aggregating httNTQ20P10. The httNT aggregation reaction was carried out to 800 hrs, at which time W17 remained completely solvent exposed (not shown). (B) Time course monitored by HPLC sedimentation assay (——◆——), R2=0.983, S.E.= ±6.0), thioflavin T fluorescence (——Δ——, R2=0.994, S.D.= ±3.9) and right angle light scattering (---○---, R2=0.983, S.D.= ±6.0). Inset, first 10 hrs. (C) Dot blots of httNTQ30P6 (F17W) time points using the antibody MW1. Top row: unfractionated aliquots of the reaction mixture (time in hrs; M = non-incubated monomer). Bottom row: equivalent masses of isolated aggregates (no material in the “M” column in this row).
Time course of aggregation of httNTQ20P10 by multiple analyses. (A) Trypsin sensitivity of either monomer (t = 0) or aggregates isolated by centrifugation at either 42 or 700 hours (see Methods). (B) Properties of isolated aggregates: fluorescence emission maxima of Trp residues in the mutant peptides F11W (——•——, R2=0.994, S.D.= ±0.5) and F17W (····▲····, R2=0.916, S.D.= ±1.2); elongation rate constants for biotinyl-Q29 for isolated aggregates adherent to microtiter plate wells (---□---, R2=0.748, S.D.= ±0.19). (C) Overall aggregation kinetics of WT peptide monitored by the HPLC sedimentation assay (---◆---, R2=0.992, S.D.= ±3.1) and by ThT fluorescence (——Δ——, R2=0.974, S.D.= ±6.0). (D) Dot blot of non-incubated monomer (M) and isolated aggregates developed with to the anti-polyQ MW1 antibody. (E) Fourier transform infrared (FTIR) spectra of aggregates. Monomeric Q15 (a); aggregates of httNTQ20P10 (F17W) isolated at 45 hrs (b), 120 hrs (c), and 120 days (d); aggregates of httNTQ36P10 isolated at 7 days (e); aggregates of Q30 isolated at 30 days (f). Amide I frequency values normally assigned to secondary structural features
Mechanism of httNT mediated exon1 aggregation. The httNT domain (green) unfolds in a polyQ repeat length dependent fashion and, once unfolded, self-aggregates without a nucleation barrier to form oligomers with cores comprised of httNT and not polyQ (red). The next identified aggregates involve both httNT and polyQ in amyloid-like structure, while oligo Pro (black) is not incorporated into the core. This drawing is schematic and is not meant to imply any details of aggregate structure, except that final aggregates are rich in β-sheet, are fibrillar, and involve both httNT and polyQ. Although the initial formation of oligomers exhibits non-nucleated, downhill kinetics, it is likely that a nucleation event takes place stochastically within the oligomer population – as shown in brackets - to trigger rapid amyloid growth.
Amino acid sequences of exon1 related peptides.
|
|
|
|---|---|
| Human htt exon 1 | MATLEKLMKA FESLKSF--- QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQ----- PPPPPPPPPP-Htt-C |
| Q15 | KK QQQQQQQQQQ QQQQQ----- ---------- ---------- KK |
| Q20 | KK QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- KK |
| Q29 | KK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQ- ---------- KK |
| Q30 | KK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ ---------- KK |
| Q35 | KK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQ----- KK |
| Q35P10 | KK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQ----- PPPPPPPPPP KK |
| httNTQ35 | MATLEKLMKA FESLKSF--- QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQ----- KK |
| Q35httNT | KK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQ----- MATLEKLMKA FESLKSF |
| httNT | MATLEKLMKA FESLKSF-amide |
| httNTQ3(F17W) | MATLEKLMKA FESLKSW--- QQQ |
| FRET-httNTQ3 | ¥ATLEKLMKA FESLKSW--- QQQ |
| httNTQ15(F17W) | MATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQ----- ---------- ---------- KK |
| httNTQ25(F17W) | MATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQQQQQQ QQQQQ----- ---------- KK |
| httNTQ30P6 | MATLEKLMKA FESLKSF--- QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ ---------- PPPPPP---- KK |
| httNTQ30P6(F17W) | MATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ ---------- PPPPPP---- KK |
| httNTQ20P10 | MATLEKLMKA FESLKSF--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| httNTQ20P10(F->A) | MATLEKLMKA AESLKSA--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| httNTQ20P10(M->O) | OATLEKLOKA FESLKSF--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| httNTQ20P10(F->A/M->O) | OATLEKLOKA AESLKSA--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| httNTQ20P10(F17W) | MATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| httNTQ20P10(F11W) | MATLEKLMKA WESLKSF--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| FRET-httNTQ20P10 | ¥ATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQQQQQQ ---------- ---------- PPPPPPPPPP KK |
| httNTQ37P10(F17W) | MATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQQ--- PPPPPPPPPP KK |
| FRET-httNTQ37P10 | ¥ATLEKLMKA FESLKSW--- QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQQ--- PPPPPPPPPP KK |
| httNTK2Q36 | MATLEKLMKA FESLKSF-KK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQ---- KK |
| Biotinyl-Q29 | BKK QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQ- ---------- KK |
Htt-C = PQLPQPPPQA QPLLPQPQPP PPPPPPPPGP AVAEEPPLHR P; ¥ = nitroTyr; O = methionine sulfoxide; B = biotin